Intercell is an innovative biotechnology company focused on the design and development of novel vaccines for the prevention and treatment of infectious diseases. Our products target markets with substantial unmet medical needs.
A listed stock corporation since 2005
Intercell is listed on the Vienna stock exchange (VSE) under the symbol “ICLL” since February 2005.
Keep updated with latest data on Intercell shares.
Intercell has a total of 48,480,486 issued shares of common stock, which includes 348,389 shares of treasury stock. See percentage of our major shareholders.
See a list of the institutes and analysts who regularly deal with economic analysis of Intercell.
Ordinary Shareholders' Meetings are held once a year. All documents related to the last meeting are published here.
In our financial calendar you will find upcoming events ranging from the Annual General Meeting as well as investor information and dates for forthcoming reports and analysis.
Visit our download area to view and download our Annual Reports, Quarterly Reports and presentations.
Our corporate team is committed to good Corporate Governance Practice in agreement with the Austrian Code of Corporate Governance.
Our list of frequent asked questions gives you the basic information about the economic foundations of Intercell.
Do not hesitate to contact us for additional information.
Successful historic financial rounds
When founded, in 1997, Intercell managed to attract more than EUR 3.6 million in venture capital. In addition, Intercell received subsidies from the Austrian Industrial Research Promotion Fund (FFF), the Vienna Business Agency (WWFF) and the Austrian Business Angels Network. A second investment phase in 2001 resulted in a substantial infusion of new capital of EUR 27 million, which at the time was the largest venture capital transaction ever undertaken in Austria. A third financial round in 2003 raised a total of EUR 43.5 million.
In February 2005, Intercell went public on the Vienna Stock Exchange and raised EUR 52.5 million.
In June 2006, Intercell launched a Second Public Offering, which resulted in a total offering volume of EUR 110.6 million and approximately 55.4 million net proceeds for Intercell.